New talent joins the team

Welcome to Medine Kockan, our new talent!

We are thrilled to welcome Medine Kockan as our new intern in Marketing and Strategic Innovation!

She will contribute to the many projects of our team. We are excited for her to participate in our continued growth!

OTC switch approval for SitavigFrance

OTC switch approval for Sitavig® 50 mg in France

Vectans pharma is proud to announce that its one-per-episode Lauriad® aciclovir treatment tablet for herpes labialis, Sitavig® 50mg, has received the approbation of the ANSM for OTC commercialization in France. Issued from Lauriad technology, SITAVIG ensures an optimum and efficient localized concentration of acyclovir directly at the disease site.
A big step for Vectans , but also for the many patients in France prone to recurrent

Lauriad technology

Lauriad® technology in pictures

Because changing the way medicines are delivered can improve patient’s life drastically. With Lauriad® we are committed to optimizing the existing therapeutic offer, bringing out new « best-in-disease » drugs.


China's NMPA authorization

China approves authorization of commercialization for Oravig®


LORAMYC® 50 mg in Germany

Vectans Pharma is glad to inform you that BfArM granted a 3-year exemption of the sunset clause for LORAMYC® 50 mg, a muco‐adhesive buccal tablets issued from the Lauriad Technology, an innovative and patented drug delivery system ensuring targeted diffusion of Miconazole. In addition to Germany, LORAMYC® is also registered in other European countries such as the United Kingdom, France and Italy. LORAMYC® also benefits from an international presence through international licensing agreements in the United States and Asian countries.

Visuel 2

Exclusive licensing agreement with m8 Pharmaceuticals

230 Bureaux de la colline
92213 Saint-Cloud